News

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced preliminary results from a pivotal anterior uveitis trial that compared Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% dosed four times daily (QID) to Pred Forte(R) (prednisolone acetate ophthalmic suspension) 1%, dosed eight times daily. Durezol is a topical ophthalmic corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery; it was approved by the US Food and Drug Administration in June 2008. Pred Forte(R) is the registered trademark of Allergan, Inc.

MALVERN, PA, Sep 17, 2008 (MARKET WIRE via COMTEX News Network) -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the first patients have been dosed in the Company's U.S. phase IIb trial of XIAFLEX(TM) for the treatment of Peyronie's disease. Peyronie's disease is the development of a collagen plaque, or scar tissue, on the shaft of the penis that hardens and reduces flexibility, causing the penis to bend or arc during erection resulting in psychological distress and pain for the patient and often interfering with or preventing intercourse.

Pleasanton, CA – September 17, 2008 – TRIA Beauty, a leader in light-based therapeutic beauty products, announced TRIA Personal Laser Hair Removal System was named a Beauty Breakthrough at the annual Allure Best of Beauty Awards on Monday September 15th. The award ceremony was held in The Plaza, where Allure presented beauty’s best and breakthrough products with their highly coveted seal of approval.